SAN FRANCISCO, April 30, 2026 /PRNewswire/ — Dreame Technology, a global leader in smart home appliances and health technology, today held its “DREAME NEXT” themed launch event at the Palace of Fine Arts in San Francisco.

Dreame stated that this launch event aims to redefine the next generation of lifestyle, serving as the prologue to the next decade of Dreame Technology’s long-term development from a global perspective.

Among the new products, the Dreame Ring series stood out as one of the highlights of the event.

In terms of product design, the Dreame Ring achieves a breakthrough in wearing experience. It features an aviation-grade titanium alloy outer ring and a hypoallergenic epoxy resin inner ring, ensuring durability and texture while greatly enhancing skin-friendly comfort. With a thickness of just 2.5 millimeters and a weight as low as 2.6 grams, the ring delivers an almost “unnoticeable” wearing experience.

This design effectively solves the common problem of traditional smart wearables being abandoned due to discomfort, allowing users to wear the ring all day – including while sleeping – so that health observation and smart reminders become seamlessly integrated into daily life.

Three Product Lines: Deep Integration of Function and Aesthetics

The Dreame Ring series announced today includes three core products:

The first product is the Dreame AI Smart Ring. It features an ultra-compact world-leading vibration motor, pioneering refined fingertip haptic feedback technology, and integrates multiple sensors within an industry-leading ultra-thin design of just 2.5 millimeters. It provides vibrating alerts for various reminders, such as prolonged sitting, hydration, medication, and other notifications.

The second is the Dreame AI NFC Smart Ring, which serves as an “ecosystem key” by integrating access cards, keys, and digital passes for seamless connectivity.

The third is the Dreame Glow Ring, which continuously monitors heart rate, blood oxygen, body temperature, respiratory rate, and sleep structure around the clock, providing efficient sleep analysis, activity tracking, and health risk assessment.

High-Luxury Jewelry System: From Everyday Wear to Heirloom Collection

In terms of product positioning, Dreame plans to introduce high-luxury jewelry materials into its ring lineup, featuring 18K gold (yellow, white, and rose gold) and Pt950 platinum, paired with natural diamonds and precious gemstones such as sapphires, rubies, and emeralds, with support for personalized customization. The craftsmanship includes hollow carving, compound stone setting, and traditional hand-engraving techniques, with each piece finished by hand-polishing.

Dreame stated that the future direction of wearable devices is not to emphasize the presence of technology, but to allow technology to serve users invisibly. The AI high-luxury smart ring is the embodiment of this trend – it is no longer a device that needs to be “used,” but an intelligent presence that accompanies users over the long term.

About Dreame Technology
Established in 2017, Dreame Technology is a global leader in high-end consumer electronics and intelligent manufacturing with the vision to empower lives through technology. Follow us on Facebook, Instagram, TikTok and Twitter. For more information, please visit https://www.dreametech.com/.

A critical AI success gap is emerging for organisations, with 30% surveyed seeing an impact on new revenue streams.

SYDNEY, April 30, 2026 /PRNewswire/ — Most organisations have moved beyond experimenting with artificial intelligence, but few are realising its full value. New research from Harvard Business Review Analytic Services, sponsored by Appian, finds that while 59% of organisations (who are moving forward with AI to some extent) have AI in production, the majority are currently focused on incremental gains that prioritise efficiency and productivity over top-line growth.

Notably, AI has the strongest impact in bolstering productivity, not enabling growth. Respondents indicated that of the AI performance measures their organisation tracks, most see impact in productivity improvements (64%) and operational efficiency (58%), while metrics like new revenue streams (30%) and ROI (35%) are among the least likely to have improved. This points to a significant opportunity for organisations to use AI to deliver broader business outcomes and growth.

“Enterprises are at an inflection point. Instead of using AI to drive productivity, organisations must evolve to focus on business growth. That’s where Appian comes in,” said Matt Calkins, CEO of Appian. “The true potential of AI can only be realised when it moves from a standalone tool to an embedded worker that drives revenue. To get there, leaders must prioritise the foundational orchestration and rules-based guardrails required to safely apply AI to high-impact work.”

AI Still Sits Outside the Flow of Work

In most organisations, AI is being used alongside work, not built into how work gets done, limiting its ability to drive higher-level business outcomes. Only 18% of respondents report that AI is primarily integrated within workflows, while a larger share (34%) continue to use AI as standalone tools alongside processes/workflows, with another 34% reporting a mix of both approaches and 12% not yet using AI in processes/workflows at all.

Most See Some Returns on AI, but Not Yet at Scale. 

Most respondents are seeing some returns from AI investments, but only 16% report realising a high degree of measurable value. The majority describe the impact as moderate (33%), slight (36%), or have no measurable value (8%). Still, expectations remain high, as 86% agree that their organisation is looking to realise more business value from its use of AI. It’s clear that AI is delivering some results, but translating those results into meaningful, scalable business impact is proving difficult.

AI Delivers Value When Embedded in Workflows

As organisations advance their AI strategies, value is closely tied to how effectively AI is integrated into workflows and applied to operational work. Seventy-one percent of organisations embedding AI into processes realised substantial or moderate value from those efforts, according to respondents. In parallel, approximately three-quarters report strong returns from modernising legacy infrastructure/systems (76%), integrating data sources (75%), and orchestrating processes/workflows across systems/applications (73%).

Legacy Systems Continue to Limit AI’s Impact

Nearly seven in ten respondents, 69%, agree that legacy systems are limiting their ability to scale AI across the enterprise. This reinforces the need for modernisation and better integration across systems and data. Siloed or low-quality data (34%), a lack of integration across systems (31%), and a lack of AI talent/skills (30%) are also among the most commonly cited barriers to embedding AI into workflows.

AI Agent Adoption Lags in Core Operations

The research also highlights differences in how AI agents are being applied across the enterprise. Organisations are more actively deploying AI agents in areas such as software development (35%), IT operations (31%), marketing and sales (26%), and customer service (25%). In contrast, agent adoption is more limited in core operational areas such as procurement (9%), manufacturing (10%), and supply chain (11%), where processes tend to be more complex and require greater control and consistency. As organisations look to expand AI into these environments, governance becomes critical.

Most Organisations Lack the Guardrails Needed to Scale AI Agents Safely

Ninety-two percent of respondents agree that AI agents need rules-based guardrails to operate safely and effectively, yet fewer than half (48%) agree that their organisation has defined such rules (among those at organisations using, considering or exploring agentic AI). As organisations explore agentic AI systems (currently used by 25% of organisations and under consideration by 62%), the need for clearly defined processes and guardrails will become even more critical. Without clear guardrails, agents can act unpredictably across systems, increasing the risk of unintended outcomes.

Process Design Is Emerging as the Key to Unlocking AI Value

Realising the full value of AI and achieving sustainable ROI requires rethinking how work is structured and governed. According to respondents, organisations are increasingly focused on better defining rules/guardrails that AI must follow (50%), standardising processes/workflows across functions (49%), and increasing cross-functional coordination (47%) to improve the success of AI implementations.

“Organisations are adopting AI, but many haven’t integrated it into the core processes that drive business outcomes,” said Alex Clemente, managing director of Harvard Business Review Analytic Services. “Those that successfully embed AI into workflows will be better positioned to realise meaningful value.”

Read the full study. 

About the Research

In March 2026, Harvard Business Review Analytic Services, sponsored by Appian, surveyed 385 business decision makers from organisations that are exploring, piloting, or actively using artificial intelligence (AI).

About Appian

Appian provides process automation technology. We automate complex processes in large enterprises and governments. Our platform is known for its unique reliability and scale. We’ve been automating processes for 25 years and understand enterprise operations like no one else. For more information, visit appian.com. [Nasdaq: APPN]

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/appian_caption_2700px_logo.jpg

• TLX597-Tx is a PSMA^[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.
• OPTIMAL-PSMA^[2] initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification.
• Telix is developing two distinct prostate therapeutic programs, tailored to disease stage and patient condition: TLX591-Tx radio antibody-drug conjugate (rADC) in combinations with standard of care (Phase 3 in mCRPC^[3]) and TLX597-Tx intended for earlier-stage mHSPC^[4].
• Webcast today: Thursday, April 30, at 9:30 a.m. AEST (Wednesday, April 29, at 7:30 p.m. EDT). Register here: https://s1.c-conf.com/diamondpass/10053985-675tre.html

MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces dosimetry results from the randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in metastatic castration-resistant prostate cancer (mCRPC), presented at the 2026 International Prostate Cancer Symposium (IPCS 2026) held in Lugano, Switzerland. These findings support TLX597-Tx’s potential to deliver a treatment that overcomes quality-of-life challenges that currently limit the clinical utility of existing RLTs in earlier-stage metastatic prostate cancer.

TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA) is a novel PSMA-targeting small molecule RLT candidate with a highly favorable dosimetry profile. Significantly reduced radiation exposure to healthy organs, including the salivary glands and kidneys^[5], may lower the incidence of xerostomia (dry mouth) and renal toxicity and support better tolerability for patients. This dosimetry profile combined with higher tumor uptake compared to existing PSMA RLTs may deliver a wider therapeutic window and enable dose intensification to maximize tumor control while preserving patient quality-of-life.

OPTIMAL-PSMA is an open-label, multi-center, randomized, Phase 2 investigator-initiated trial (IIT) led by Professor Louise Emmett at St Vincent’s Hospital in Sydney, Australia. The study is evaluating the safety, dosimetry, and efficacy of an intensified dosing regimen of TLX597-Tx compared with a standard dose schedule in 120 men with advanced mCRPC, randomized on a 2:1 basis. The novel dose-intensification regimen delivers higher activity per cycle (8.5 GBq), delivered on day 1, day 3 and day 15, followed by 10-weekly dosing for three further cycles. The study aims to confirm that a dose intensified TLX597-Tx regimen will maximize the radiation dose to cancerous lesions when they are most vulnerable to damage and therefore improve overall response to treatment.

Telix believes these dosimetry data support further evaluation of TLX597-Tx in earlier-stage disease and is initiating OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive prostate cancer (mHSPC).

Principal Investigator for OPTIMAL-PSMA, Professor Louise Emmett, commented, “The goal of OPTIMAL-PSMA is to identify a dose regimen for TLX597-Tx that leads to deeper and longer responses without increasing toxicity for men with metastatic prostate cancer. We look forward to starting the Phase 2 OPTIMAL-E trial soon.”

Dr. David N. Cade, Group Chief Medical Officer at Telix, added, “These encouraging dosimetry results from OPTIMAL-PSMA, combined with earlier exploratory work^[6], are very promising and highlight TLX597-Tx’s potential to substantially increase the tumor dose while minimizing radiation to sensitive organs. For people living with earlier-stage metastatic disease, preserving quality-of-life alongside effective cancer control is mandatory. These findings support further study in mHSPC and reinforce Telix’s strategy to develop differentiated PSMA-targeting therapies, so clinicians may be able to tailor treatment choice to the patient’s disease stage and individual condition.”

TLX597-Tx is being developed alongside TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan), Telix’s lead antibody-based prostate cancer therapy candidate, currently the subject of the Phase 3 ProstACT Global^[7] trial in mCRPC, which is actively dosing patients in jurisdictions with regulatory approval and recently reported data from a safety and dosimetry lead-in^[8]. TLX591-Tx and TLX597-Tx exhibit complementary modes-of-action, suggesting the potential for distinct applications in mCRPC and mHSPC settings as part of Telix’s portfolio approach to treating prostate cancer. TLX591-Tx and TLX597-Tx have not received marketing authorization in any jurisdiction.

To view the webcast slides, click here.

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.